Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

Benzinga · 2d ago
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.